Publicacións nas que colabora con Maria Teresa Cedena Romero (21)

2024

  1. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

2023

  1. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  2. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161

  2. Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD

    Therapeutic Advances in Hematology, Vol. 13

  3. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria

    Leukemia Research, Vol. 116

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  2. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

  3. Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma

    Cancers, Vol. 13, Núm. 19

2020

  1. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  2. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

    Leukemia, Vol. 34, Núm. 11, pp. 3007-3018

  3. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

  4. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Blood, Vol. 136, Núm. 2, pp. 199-209

  5. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  6. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia

    British Journal of Haematology

2019

  1. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

2018

  1. Prognostic value of antigen expression in multiple myeloma: A PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials

    Leukemia, Vol. 32, Núm. 4, pp. 971-978

2017

  1. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group

    Leukemia Research, Vol. 63, pp. 85-89

  2. Depth of response in multiple myeloma: A pooled analysis of three PETHEMA/GEM clinical trials

    Journal of Clinical Oncology, Vol. 35, Núm. 25, pp. 2900-2910

  3. Differentiation stage of myeloma plasma cells: Biological and clinical significance

    Leukemia, Vol. 31, Núm. 2, pp. 382-392